1672 — Ascletis Pharma Share News
0.000.00%
Last trade - 00:00- HK$6.16bn
- HK$3.50bn
- CNY2.03m
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management
Ascletis Pharma slips on expecting deeper H1 loss on R&D expenses
Brief: Ascletis Pharma Expects HY Loss Of RMB319.7 MLN
Brief: Ascletis Pharma Initiates Two Phase I Obesity Studies In U.S. For ASC36 And ASC36_35FDC
Brief: Ascletis Pharma Initiates Global Phase III For ASC30 In Obesity
Brief: Ascletis Pharma Says ASC37 Demonstrated Superior Weight Loss In Obese Mouse Model
Brief: Ascletis Pharma Selects Fixed-Dose Combination Of Asc48 And Asc30 For Clinical Development
Factbox: Race to launch weight-loss pills heats up as smaller players advance
Ascletis hits 5-week high on new drug applications for obesity treatment
Brief: Ascletis Pharma Submits Two IND Applications To U.S. FDA For Obesity Treatment
Ascletis Pharma touches near 4-week high on share buyback plan
Brief: Ascletis Pharma To Use Up To HK$300 Million For Share Repurchase
Brief: Ascletis Pharma Receives US FDA IND Clearance For Phase I Study Of ASC35 For Obesity
Factbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval